BioMedTech startups dominate Trinity Bradfield Prize
BioMedTech companies ruled the roost in the Trinity Bradfield Prize in Cambridge – a competition which guests and judges felt brought the strongest collective pitches they had seen in the five years of the event.
Enhancements to the format ensured that every applicant had an opportunity to learn new entrepreneurial skills and network with the founders of leading local startups via a series of workshops.
Finalists confirmed that these workshops – covering business models, Intellectual Property, finding customers and pitching – helped them crystalise their thoughts and better structure their final presentations. The pitch workshop was delivered by former prize winners Molly Haugen (2021) and Abiel Ma (2022).
The overall winner, clinching £10k, was Cambridge Nucleomics – a MedTech business that offers a fully automated point-of-care sepsis test in under an hour.
Second place and £5k went to fellow MedTech startup Compound Hound which has developed a breath sensor said to boast advantages over established technologies and able to determine if a newborn child is suffering from jaundice.
The Hellings Prize and £5k went to biotech company BioTryp Therapeutics, which has developed a new class of biofilm inhibitors, providing an alternative to traditional antibiotic treatments.
As well as the cash prizes all the finalists will benefit from mentoring and complementary membership of The Bradfield Centre at Cambridge Science Park where the competition was staged.
Nobel Prize Laureate, Sir Greg Winter, who is chair of judges, announced an additional new prize for next year's competition. The Angel Prize will be awarded to the team that can demonstrate the most progress towards their stated milestones: 2022 and 2023 finalists from the Trinity Bradfield Prize are eligible.